The metabolism and mode of action of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) were studied in herpes simplex virus type 1 (HSV-1)-infected and uninfected MRC-5 cells and compared with those of acyclovir. In uninfected cells incubated with 10 ,uM acyclonucleoside for 4 h, no phosphorylation of either BRL 39123 or acyclovir was detected. In contrast, in HSV-1-infected cells, both BRL 39123 and acyclovir were phosphorylated up to the triphosphate esters. Phosphorylation of BRL 39123 occurred much more rapidly and proceeded to a greater extent than did that of acyclovir. Furthermore, following the removal of acyclonucleoside from the culture medium, the intracellular triphosphate ester of BRL 39123 was much more stable than was that of acyclovir, the half-lives being about 10 and 0.7 h, respectively. BRL 39123 treatment effectively inhibited the formation of HSV-1 DNA in infected MRC-5 cells, 50% inhibitory concentrations of BRL 39123 and acyclovir being 0.04 ,Lg/ml (0.16 ,uM) and 0.15 ,ug/ml (0.67 ,IM), respectively. In addition, BRL 39123 was shown to be more effective than acyclovir at inhibiting viral DNA synthesis following short treatment times, presumably reflecting the greater stability of BRL 39123 triphosphate. Neither BRL 39123 nor acyclovir inhibited cellular DNA synthesis in uninfected cells at concentrations of up to 100 jig/ml.
The discovery of the selective antiherpesvirus activity of acyclovir (16) and its subsequent clinical use for herpes genitalis, herpes labialis, and herpes zoster have stimulated much interest in other acyclonucleosides. Following improved synthesis (10, 11) , the virological evaluation (2, 3) of 9-(4-hydroxy-3-hydroxymethylbut-1-yl)guanine (BRL 39123) indicated that this compound had a spectrum of antiviral activity similar to that of acyclovir and a similar low toxicity for uninfected cells. However, it had a more persistent antiviral effect than did acyclovir. Larsson et al. (14) showed that this acyclonucleoside, at a concentration of 250 ,uM, was readily phosphorylated by herpes simplex virus type 1 (HSV-1) thymidine kinase but was not phosphorylated by the thymidine kinase from Vero cells. This result suggests that the antiviral activity of BRL 39123 may occur via a phosphorylated metabolite of BRL 39123.
In this paper, we describe the phosphorylation kinetics in human cells infected with HSV-1 of BRL 39123 at concentrations (10 and 1 jiM) that have been achieved in the plasma of volunteers (M. R. Boyd, R. Boon, S. E. Fowles, K. Pagano, D. Sutton, R. A. Vere Hodge, and B. D. Zussman, Antiviral Res. 9:146, 1988) .
We compared the formation and stability of the triphosphate of BRL 39123 with those of the triphosphate of acyclovir. BRL 39123 and acyclovir were also evaluated for their inhibition of viral DNA synthesis, particularly after short drug treatment times. The results of these studies provide a biochemical rationale for the persistent antiviral activity of BRL 39123 described by Boyd et al. (2, 3) . rity was determined to be 97% by thin-layer chromatography. [2'-3H]acyclovir (specific activity, 688 MBq/,umol) was obtained from NEN Research Products, Du Pont (UK) Ltd., Stevenage, United Kingdom. The radiochemical purity was determined to be 99% by thin-layer chromatography. The radiolabeled acyclovir was diluted 25or 50-fold with unlabeled acyclovir (Zovirax; Wellcome Foundation Ltd., London, United Kingdom). [a-32P]dCTP (approximately 111 TBq/mmol) for the preparation of DNA probes and [6-3H] thymidine (74 GBq/mmol) for thymidine incorporation studies were obtained from Amersham International Plc., Little Chalfont, United Kingdom.
Cells and viruses. MRC-5 cells were grown by standard cell culture techniques. HSV-1 strain SC16 (12) was obtained from H. J. Field, Department of Pathology, University of Cambridge, Cambridge, United Kingdom. Stocks were passaged in BHK-21 cells, and the virus was grown in MRC-5 cells just prior to use.
For measurement of the volume of MRC-5 cells, a sample of trypsinized uninfected cells (106) was pelleted by centrifugation in a micro-hematocrit centrifuge (Hawksley; Lancing, United Kingdom) and shown to have a packed-cell volume of approximately 4 R1 (mean of four determinations).
HPLC equipment. For high-pressure liquid chromatography (HPLC), samples were injected from a Waters WISP and chromatographed on a Waters Nova-Pak C18 cartridge (inner diameter, 5 mm) fitted in a Z-module (Millipore Corp., Bedford, Mass.). A Waters C18 Guard-PAK precolumn was used to protect the analytical column. The eluate was monitored at 254 nm with a Spectroflow 757 detector (Kratos Analytical Instruments, Ramsey, N.J.) and mixed with scintillant (Monofluor; Lablogic Ltd., Sheffield, United Kingdom) in a micro-mixer T-piece (Lee Products Ltd., Chalfont St. Peter, United Kingdom), and the radioactivity was monitored by an ISOFLO detector fitted with a Teflon cell (0.5 ml; Nuclear Enterprises Ltd., Reading, United King-dom). The signal from the Kratos detector was recorded by a Waters data module (M730), and that from the ISOFLO detector was recorded on disk by an Apple computer. The chromatographic system, including Waters M45 and M510 pumps, was controlled by a Waters M720 module.
Preparation of cell extracts and HPLC analysis of samples taken during the formation of BRL 39123 phosphates. MRC-5 cells grown in 25-cm2 flasks were infected with HSV-1 SC16 at a low multiplicity of infection (0.01 PFU per cell) and incubated for 20 h. The antiviral compounds were added by replacing the cell culture medium with fresh medium (3 ml) containing [3H]BRL 39123 or [3H]acyclovir at 10 or 1 ,uM, and the cultures were incubated at 37°C for various times. The medium was removed and added to an equal volume of ethanol to inactivate any virus present prior to HPLC analysis. The cell monolayer was washed quickly (3 s) with phosphate-buffered saline (10 ml), and the cells were extracted with phosphate-buffered ethanol (3 ml of 50% ethanol in 10% phosphate-buffered saline) for 1 min. Finally, the cell monolayer was solubilized in 0.2% sodium dodecyl sulfate (3 ml) to ensure that the major part of the radioactivity had been extracted by the phosphate-buffered ethanol. Although solutions containing 50% ethanol could be analyzed by HPLC if a small (s-10-RI) injection volume was used, the samples of phosphate-buffered ethanol were generally evaporated to dryness under reduced pressure and dissolved in 5 mM K2HPO4-1 mM heptyltriethylammonium phosphate at five times the original concentration. The samples were analyzed for the nucleoside and for mono-, di-, and triphosphate esters on a Waters Nova-Pak C18 column. Elution was done with a linear gradient from 95% buffer A (5 mM KH2PO4, 1 mM heptyltriethylammonium phosphate [pH 5])-5% buffer B (15 mM KH2PO4 in 70% MeOH) to 60o buffer A-40% buffer B. To increase the sensitivity of detection by the radioactivity monitor, we reduced the flow rate during elution to 0.5 ml/min.
The retention times for BRL 39123 and its mono-, di-, and triphosphate esters were about 12, 18, 23, and 26 min, respectively. The assignment of these peaks was confirmed by using synthetic standards. By analogy, the peaks with retention times of 8, 15.5, 21.5, and 23.5 min were assigned to acyclovir and its phosphate esters. The peak areas were calculated by the Apple computer with a chromatography program supplied by Nuclear Enterprises Ltd. The efficiency of radioactivity counting was constant throughout the HPLC gradient. Thus, the concentrations of the phosphate esters were calculated by using a sample of the corresponding acyclonucleoside as a standard.
Stability of triphosphates of BRL 39123 and acyclovir in infected cells. MRC-5 cells in 25-cm2 flasks were infected with HSV-1 SC16 at about 1 PFU per cell. After 1.25 h, medium with [3H]BRL 39123 or [3H]acyclovir was added to give a final compound concentration of 10 ,uM. The flasks were incubated at 37°C for 5.5 h. The medium was removed, the cells were washed with phosphate-buffered saline (50 ml), and fresh medium (50 ml) was added. The stability of the triphosphates in the cells was determined by harvesting flasks at various times and assaying the supernatant cell extracts by HPLC as described above. The extracellular concentrations of BRL 39123 and acyclovir at the first sampling time (1 min) were 4 and 1.6 nM, respectively. Amounts of acyclovir phosphates which were below the in microdilution plates were infected with HSV-1 SC16 at 1 PFU per cell. The monolayers were treated with either BRL 39123 or acyclovir at concentrations of between 30 and 0.01 ,ug/ml in triplicate as described previously (3) . The viral DNA content of drug-treated cultures at 24 h was determined by hybridization with an HSV-1 DNA in a manner similar to that previously described by Gadler et al. (7) . The HSV-1 DNA probe was prepared from plasmid pHSV106, consisting of the BamHI 0 fragment of HSV-1 strain MP cloned in pBR322 (provided by P. O'Hare, Marie Curie Memorial Foundation, The Chart, United Kingdom). The probe was shown to bind specifically to HSV-1-infected MRC-5 cell samples, with no evidence of binding to uninfected cells.
Effect of BRL 39123 and acyclovir on MRC-5 cell DNA synthesis. DNA synthesis in uninfected MRC-5 cells was measured by a DNA probe system analogous to that used to monitor the levels of HSV-1 DNA and by the incorporation of [6-3H]thymidine into cellular DNA.
For DNA probe studies, MRC-5 cells were plated into wells of microdilution plates at a low level of seeding (2 x 103 cells per well) and grown in the presence of various concentrations of drug for 4 days. The effect of each drug on cellular DNA synthesis was determined by DNA hybridization with a human DNA probe. Plasmid BLUR-8, containing a 300-base-pair repeat sequence from human DNA (Alu), was used as the hybridization probe for human DNA.
For [3H]thymidine incorporation studies, MRC-5 cells were transferred into wells of microdilution plates at 104 cells per well in Eagle minimum essential medium-10% fetal calf serum containing various concentrations of either BRL 39123 or acyclovir (100 to 0.3 ,ug/ml) in triplicate. After 4 days of growth in the presence of the drug, the cells were pulse-labeled with [6-3H]thymidine (0.5 ,uCi per well) for 5 h at 37°C in the presence of the drug. Cells were released from microdilution plate wells by trypsinization and lysed with water, and the DNA was adsorbed onto glass fiber filters by using an automated cell harvester (Dynatech Laboratories Ltd., Billingshurst, United Kingdom). [6-3H]thymidine incorporated into cellular DNA was retained on the filter while unincorporated material passed through. After the filters were dried, the amount of [6-3H]thymidine present in each filter was determined by scintillation counting with Omnif- . At the indicated times, cells were extracted and the samples were assayed by HPLC as described in the text. For BRL 39123 triphosphate in panels a and b, the lines, fitted by linear regression, are given by the equations y = 5.4x -1.5, r = 0.993; and y = 0.53x + 0.95, r = 0.987; respectively. TP, Triphosphate; DP diphosphate; MP, monophosphate. luor scintillant and an LS8100 scintillation counter (Beckman, High Wycombe, United Kingdom). Typically, approximately 12 to 14 kcpm of3H were incorporated per well with untreated cells.
RESULTS
Analysis of BRL 39123, acyclovir, and their phosphate esters in virus-infected cells. The use of radiolabeled acyclonucleosides allowed the assay of the antiviral compounds and their phosphate esters without interference from natural nucleosides and nucleotides. The HPLC trace for extracts of infected cells obtained at various times after the addition of BRL 39123 is shown in Fig. 1 . Concentrations of acyclovir and its phosphate esters were similarly determined.
Initially, the phosphates of BRL 39123 were extracted from cellular material under acidic conditions, but it was found that they were not stable. However, extraction with ice-cold phosphate-buffered ethanol as described previously for acid-labile metabolites (17) and also for buciclovir phosphates (19) was found to be most satisfactory for both BRL 39123and acyclovir-treated cells.
Uptake of BRL 39123 and acyclovir into cells. To remove extracellular acyclonucleoside and yet minimize diffusion out of the cells, we washed infected monolayers rapidly (3 s) with a large volume of phosphate-buffered saline. After incubation with either BRL 39123 or acyclovir for only 1 min, the levels of acyclonucleoside in cell extracts were generally about 20 to 40 pmol/106 cells. As these amounts of acyclonucleosides were much higher than the corresponding levels of triphosphate esters, the rates of uptake of drugs into the cells were clearly not limiting the rates of phosphorylation.
Phosphorylation of BRL 39123 and acyclovir in cells. In uninfected MRC-5 cells incubated with 10,uM BRL 39123 or acyclovir for 4 h, no phosphates of BRL 39123 or of acyclovir were detected (limit of detection, 1 pmol/106 cells).
Both BRL 39123 and acyclovir were phosphorylated within infected cells (Fig. 2 ). During incubation of infected cells with 10 jxM BRL 39123, the major phosphorylated derivative was the triphosphate ester ( Fig. 2a ). Even after incubation for only 1 min the levels of di-and triphosphate esters were 2 and 3 pmol/106 cells, respectively.
During the 4-h incubation, the levels of BRL 39123 triphosphate continued to increase up to 1,200 pmol/106 cells (equivalent to about 300 ,uM). The average rate of formation of BRL 39123 triphosphate during the 4-h incubation was 1,360 pmol/(min g of cells). Initially, the proportion of BRL 39123 triphosphate, as a percentage of the total phosphorylated derivatives, was about 60%; it increased to about 80% after 10 min. Thereafter, the proportions of mono-, di-, and triphosphate esters remained about 1:10:40, respectively.
Following incubation with 1 ,uM BRL 39123, the concentrations of the mono-, di-, and triphosphate esters were about 1/10 those found following incubation with 10 ,uM BRL 39123 (Fig. 2b) . After 4 h of incubation, the level of BRL 39123 triphosphate was 130 pmolI106 cells (equivalent to about 33 jiM), and the average rate of formation was 133 pmol/(min g of cells).
Throughout the incubation, the extracellular concentrations of BRL 39123 remained at about the initial concentrations. Hence, after incubation for 4 h with either 10 or 1 ,uM BRL 39123, the intracellular concentration of BRL 39123 triphosphate was about 30-fold higher than that of BRL 39123 in the cell culture medium.
In contrast to the rapid phosphorylation of BRL 39123, acyclovir, even at the higher concentration (10 ,uM), was 0OACV 20 phosphorylated slowly to give relatively low levels of phosphate esters. After incubation with acyclovir from 40 min until 4 h, the triphosphate levels were between 6 and 10 pmol/106 cells (Fig. 2c ). The proportions of the mono-, di-, and triphosphates of acyclovir differed markedly from those of BRL 39123 in that the mono-and triphosphate esters of acyclovir were found in comparable amounts, with only low or trace amounts of the diphosphate ester (Fig. 2c ). When acyclovir was tested at 1 ,uM, no phosphate esters were detected, as would be expected if the level of phosphorylation was 1/10 that of acyclovir at 10 p.M.
Stability of intracellular phosphate esters of BRL 39123 and acyclovir in HSV-1-infected cells. Figure 3 shows the stabilities of the phosphate esters of BRL 39123 and acyclovir following the removal of extracellular drug. After incubation of virus-infected cells with [3H]BRL 39123 or [3H]acyclovir from 1.25 to 5.5 h postinfection and after washing of the cells, the intracellular triphosphate ester levels were 2,800 and 57 pmol per flask, respectively, and the residual extracellular concentrations of the corresponding acyclonucleosides were 4 and 2 nM, respectively. During the next 8 h of incubation, the concentrations of BRL 39123 phosphates decreased slowly, the level of triphosphate ester being reduced to about one-half the initial level (Fig. 3a) . In contrast, the concentrations of acyclovir phosphates decreased much more rapidly, the levels being below the detection limit within 4 h (Fig. 3b ). Under these conditions, the half-lives of the triphosphates of BRL 39123 and acyclovir were about 10 and 0.7 h, respectively.
As the amounts of acyclonucleotides within the cells decreased, the resulting acyclonucleoside diffused out of the cells into the culture medium. In the cell culture treated with BRL 39123, the concentration of BRL 39123 in the medium increased linearly throughout the 8-h incubation period. In contrast, acyclovir concentrations initially increased rapidly but reached the maximum level after 2 h (Fig. 3c ), by which time virtually all of the acyclovir phosphates had been converted to acyclovir.
Effect of BRL 39123 and acyclovir on HSV-1 DNA synthesis. Preliminary experiments demonstrated that BRL 39123 was a potent inhibitor of HSV-1 DNA synthesis, with almost a complete shutoff of viral DNA synthesis at drug concentrations above 3 ,ug/ml (11.8 ,uM) .
To determine a 50% inhibitory concentration of each compound it was important to establish that the DNA probe concentration was not limiting, thereby reducing hybridization to the virus control relative to drug-treated samples. When various dilutions of the virus control were incubated with the DNA probe at the same time as drug-treated samples, there was clearly a linear relationship between probe binding and virus control dilution. Therefore, under these conditions, probe binding to the virus control is an accurate estimate of the viral DNA content.
The dose response for the inhibition of HSV-1 DNA synthesis by BRL 39123 and acyclovir is shown in Fig. 4 . The 50% inhibitory concentrations of BRL 39123 and acyclovir were calculated to be 0.04 ,ug/ml (0. -3H]acyclovir (ACV) was added from 1.25 to 5.5 h after infection. Then the cell cultures were washed and, at the indicated times, cells were extracted and the samples were assayed by HPLC as described in the text. The extracellular concentrations of the acyclonucleosides were calculated from the measurement of radioactivity in a sample (50 ,ul) taken at each of the indicated times. In those samples also assayed by HPLC, radioactivity was present only in the peak corresponding to the acyclonucleoside. See the legend to Fig. 2 for definitions of TP, DP, and MP. showed better inhibitory activity than did acyclovir at concentrations of 0.1 ,ug/ml and above.
Effect of duration of drug treatment on inhibition of DNA synthesis. MRC-5 cells were infected with HSV-1 at approximately 1 PFU per cell, and drug was added 5 h postinfection, by which time viral thymidine kinase should have been produced. Drug was removed at various times thereafter and replaced with drug-free medium. Levels of viral DNA were determined 24 h postinfection by hybridization with a radiolabeled HSV-1 DNA probe. Preliminary experiments showed that an increase in viral DNA content was not detectable until 6 to 8 h postinfection (data not shown).
Treatment of HSV-1-infected cells for 2 h clearly resulted in a more effective inhibition of viral DNA synthesis by BRL 39123 than by acyclovir (Fig. 5a ). Markedly reduced levels of viral DNA were present in cells treated with 1, 3, and 10 ,uM BRL 39123 for 2 h (69, 76, and 91% reductions, respectively), while cells similarly treated with 10 ,uM acyclovir showed only a 41% reduction in viral DNA. However, when the duration of treatment was extended to 19 h, both BRL 39123 and acyclovir showed good inhibition of viral DNA synthesis at 1, 3, and 10 ,uM (Fig. Sb) . While BRL 39123 still appeared to show more effective antiviral activity than did acyclovir with this treatment time, the difference was much smaller than the 2-h treatment time.
Effect of BRL 39123 on MRC-5 cell DNA synthesis. To prove a selective inhibition of viral DNA synthesis by BRL 39123 it is important to demonstrate a lack of effect on cellular DNA synthesis. Experiments were thus carried out to investigate the effect of the drug on cellular DNA synthesis by using either an Alu DNA probe method, analogous to the method used for the quantitation of HSV-1 DNA, or a [3H]thymidine incorporation method. Incorporation of radiolabeled thymidine into cellular DNA is a commonly used method for measuring ongoing DNA synthesis.
MRC-5 cells were grown for 4 days in medium containing BRL 39123 or acyclovir. Levels of cellular DNA were then quantitated by using the Alu DNA probe and [3H]thymidine. Neither BRL 39123 nor acyclovir at concentrations as high as 100 ,ug/ml (395 ,uM for BRL 39123 and 444 ,M for acyclovir) had a significant effect on the levels of probe a. 2 hour duration (Table 1) . BRL 39123 can thus inhibit HSV-1 DNA synthesis at concentrations at least 2,500 times lower than those required to inhibit cellular DNA synthesis.
DISCUSSION
The experiments in this report were designed to provide information about the biochemical mechanism for the selective antiviral action of BRL 39123 and to compare the mode of action of BRL 39123 with that of acyclovir. Virological studies indicated that BRL 39123 has a more persistent antiviral action than does acyclovir (3). A biochemical rationale for these effects was sought.
The conditions were chosen to be as relevant as possible to the clinical situation. We used human cells instead of monkey cells (5, 19) , and the drug concentrations (generally <10 ,uM) we used are achievable in humans. The cells were infected with a small virus inoculum (0.01 PFU/ml) so that, as in a natural infection, they would become infected over a period of time and, therefore, virus replication would be at different stages when the drug was added. When comparing the rates of phosphorylation of BRL 39123 and acyclovir, we added the compounds 20 h after infection of the culture, when adequate levels of viral thymidine kinase should have been present in many of the cells. If the acyclonucleosides had been added within 1 h of infection, even with a high virus inoculum (>1 PFU per cell), following the protocol of others (5, 19) , then the initial rate of phosphorylation of the acyclonucleosides probably would have been limited by the lack of viral thymidine kinase (1) . During incubation under our conditions, the levels of acyclovir triphosphate remained low (see below) and were not as high as those obtained by others (5, 19) . The latter conditions were used, however, to investigate the stability of the triphosphates, because it was necessary to start with a relatively high level of acyclovir triphosphate.
BRL 39123 was found to be rapidly taken up by uninfected and HSV-1-infected MRC-5 cells. In this respect BRL 39123 was similar to other natural nucleosides and antiviral acyclonucleosides (reference 19 and references therein). As for other acyclonucleosides, the rate of uptake into the cells did not appear to limit the rate of phosphorylation.
When either BRL 39123 or acyclovir at 10 ,uM was incubated with uninfected MRC-5 cells, no phosphates of either acyclonucleoside were detected. Furthermore, the selective inhibitory activity of BRL 39123 for viral, as opposed to cellular, DNA synthesis was clearly demonstrated by the Alu DNA probe and thymidine incorporation tests (Table 1 ). In uninfected cells, there was no effect on cellular DNA synthesis at concentrations of BRL 39123 that were 2,500 times higher than those required to inhibit viral DNA synthesis. These results correlate with the lack of effect of BRL 39123 on MRC-5 cell growth (3) . Therefore, the selective activity of BRL 39123 for the inhibition of viral, but not cellular, DNA synthesis, like that of acyclovir, appears to be the result, at least in part, of the inability of human cellular enzymes to phosphorylate the acyclonucleoside.
In HSV-1-infected MRC-5 cells in which viral thymidine kinase was presumably present, BRL 39123 was extensively phosphorylated to the triphosphate ester. This result suggests that BRL 39123 triphosphate, like acyclovir triphosphate, is the metabolite that actually inhibits the replication of the herpesvirus. The synthesis of viral DNA was found to be inhibited when BRL 39123 was added to HSV-1-infected cells. The similarity between the drug concentration required to inhibit viral DNA synthesis and that required to inhibit virus production (3) supports the concept that the antiviral mode of action of BRL 39123 is principally at the level of DNA synthesis.
In comparison with acyclovir, BRL 39123 was phosphorylated far more quickly when cells infected several hours previously were treated. During only the initial part of the incubation with 10 ,uM acyclovir, the rate of formation of acyclovir triphosphate was comparable to that (33 pmol/[min * g of cells]) previously reported for 100 puM acyclovir in Vero cells (5, 15) . In contrast, BRL 39123 was phosphorylated continuously throughout the incubation period of 4 h, the rates of formation of the triphosphate ester being 1,360 and 133 pmol/(min g of cells) for BRL 39123 at 10 and 1 ,uM, respectively. The faster phosphorylation of BRL 39123 than of acyclovir was reflected in the times of incubation at which the triphosphate esters were first detected; for acyclovir, the triphosphate was first detected after 40 min of incubation, whereas for BRL 39123, the triphosphate was found after incubation for only 1 min. Also, BRL 39123 was phosphorylated to a much greater extent than was acyclovir. At either 1 or 10 ,uM, the concentration of BRL 39123 triphosphate inside the cells after 4 h of incubation was about 30-fold higher than that of BRL 39123 in the medium. In contrast, the concentration of acyclovir triphosphate inside the cells was at least 4-fold lower than that of acyclovir in the medium.
Furman et al. (6) suggested that the decrease in the intracellular levels of acyclovir triphosphate, even in the continued presence of acyclovir, may be the result of degradation (for example, to guanine nucleotides) and leakage of the drug from infected cells. If the membrane of infected cells became permeable to triphosphate nucleotides, then the loss of BRL 39123 triphosphate would be expected. However, an alternative explanation may be that the equilibrium between acyclovir and its phosphates is shifted by the reduced rate of acyclovir monophosphate formation, which is inhibited by the increasing concentrations of thymidine (9) and thymidine triphosphate (13) found in acyclovir-treated HSV-1-infected cells. Both thymidine (Ki,m 0.4 ,uM) (14) and thymidine triphosphate (Ki, about 100 ,uM) (8) seem to have a higher affinity for the viral thymidine kinase than does acyclovir (Ki, 173 ,uM) (4). In contrast, the phosphorylation of BRL 39123 would continue, albeit at a slightly reduced rate, as this compound appears to have a high affinity for the viral enzyme (Ki, 1.5 p.M) (14) .
Following the removal of the acyclonucleoside from the cell culture medium, the stability of the triphosphate of BRL 39123 was much greater than that of the triphosphate of acyclovir, the half-lives being 10 and 0.7 h, respectively. The stabilities of the triphosphate esters of BRL 39123, 9-(1,3dihydroxy-2-propoxymethyl)guanine (DHPG; 18), and buciclovir (19) are similar and differ markedly from that of the triphosphate ester of acyclovir. Thus, the proposed active metabolite of BRL 39123, but not that of acyclovir, is efficiently trapped at high concentrations within the herpesvirus-infected cells. This entrapment of the triphosphate of BRL 39123 suggests that BRL 39123 may inhibit viral replication much more effectively than acyclovir when treatment times are reduced. To test this hypothesis we investigated the effect of these compounds on HSV-1 DNA synthesis following either extended (19-h) or short (2-h) treatment periods. After the extended treatment, we showed that BRL 39123 was marginally more effective in reducing viral DNA synthesis than was acyclovir, correlating with the result of the virus yield test reported previously (3) . In contrast, after the short treatment, BRL 39123 inhibited viral DNA synthesis markedly more effectively than did acyclovir. We believe that this enhanced antiviral effect is the result of the efficient trapping of the active metabolite of BRL 39123 within the virus-infected cells.
In summary, the mechanism of action of BRL 39123 seems to involve its transformation into a triphosphate in virusinfected cells and the inhibition of viral DNA synthesis. The triphosphate is rapidly formed in such cells, accumulates in them, and has a long half-life. During treatment of clinical herpesvirus infection, BRL 39123 would be expected to remain trapped within the infected cells even when the concentration of BRL 39123 in the blood drops to a low level. Thus, it should be possible to treat herpesvirus infections with BRL 39123 at a dosage frequency lower than that used for acyclovir.
